UPDATE: Roth Capital On Applied Genetic Technologies Buy Rating: Firm Highlights Release Of Phase 1/2 Data For AGTC-401/402 As 'Limited Improvements' Seen In Adult CNGA3-Patients But 'Encouraging Improvements' In Adult CNGB3-Patients.